Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
  Report  
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Astellas Pharma : Transfer of Distribution Rights for Targocid® and Maalox®

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/09/2011 | 04:10am CEST

Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo; Representative Director and President: Jez Moulding) announced that Astellas Pharma will transfer the rights to distribute the injectable antibiotics Targocid® (generic name: teicoplanin) and the treatment for peptic ulcer and gastritis Maalox® (generic name: dried aluminum hydroxide gel and magnesium hydroxide) to sanofi-aventis effective on January 1, 2012. This transfer of distribution rights is taking place based on the expiration of the contract.

<Products for which distribution rights will be transferred>

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTELLAS PHARMA INC
04/23ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/19ASTELLAS PHARMA : Findings on Immunoglobulins Discussed by Investigators at Aste..
AQ
04/16ACTINIUM PHARMACEUTICALS : to Showcase Capabilities of its AWE Technology Platfo..
AQ
04/12ASTELLAS PHARMA : Named "Outstanding Employer" for Supporting Employees with Mil..
AQ
04/12ASTELLAS PHARMA : New Colitis Data Have Been Reported by Investigators at Astell..
AQ
04/05SEATTLE GENETICS : and Astellas Receive FDA Breakthrough Therapy Designation for..
AQ
04/05ASTELLAS PHARMA : Studies from Astellas Pharma in the Area of Nephropathy Descri..
AQ
04/03ASTELLAS PHARMA : to Participate in 'Neglected Tropical Diseases Drug Discovery ..
AQ
04/02ASTELLAS PHARMA : Announces Personnel Change
AQ
More news
News from SeekingAlpha
04/20Key events next week - healthcare 
04/19Astellas sells certain U.S. research facilities to Gilead 
03/283 THINGS IN BIOTECH, MARCH 27 : Roche Rips, Loxo Rolls, Astellas Rams 
03/26Seattle Genetics' enfortumab vedotin a Breakthrough Therapy for urothelial ca.. 
03/193 THINGS IN BIOTECH, MARCH 18 : Exelixis Lives, Astellas Digs Deeper, Alexion Eq.. 
Financials ( JPY)
Sales 2018 1 299 B
EBIT 2018 220 B
Net income 2018 179 B
Finance 2018 338 B
Yield 2018 2,28%
P/E ratio 2018 17,28
P/E ratio 2019 16,31
EV / Sales 2018 2,26x
EV / Sales 2019 2,19x
Capitalization 3 273 B
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 625  JPY
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, Chief Executive Officer & Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Roderick Christmon Executive Director-Medical & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC8.55%30 402
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY7.07%158 571